Back to Peptipedia
MetabolismHuman research

Survodutide

Survodutide is investigated clinically as a dual glucagon/GLP-1 receptor agonist.

Peptipedia explains research and prescribing information. It does not replace medical advice and is not an invitation to use a substance.

Research areas

Source-based short profile

Evidence matrix

Molecular identity
Confirmed

Survodutide (BI 456906) is a defined dual glucagon/GLP-1 receptor agonist peptide from clinical studies. Unspecified marketed forms must be distinguished from it.

Human research
Moderate
Replication
Single research group
Clinical endpoints
Symptom- or function-related
Safety
Limited characterization
Approval
No documented approval

The dimensions are presented separately and are not combined into an overall score.

What the source shows

The linked clinical publication studies weekly administration in adults with obesity.

Research gaps

  • ·The trial product should not be equated with an arbitrary research product.
  • ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.